Professor Jerzy Nawrocki
Vitreq has good instruments and the potential to develop an important role in the market.
Professor Jerzy Nawrocki received his medical degree from the Medical University of Lodz in Poland. He subsequently trained as an Ophthalmologist at Munich University in Germany and later was awarded a Professorship in Ophthalmology. Professor Nawrocki is the President and a Founding and Board Member of the European Vitreoretinal Society. He is also a Member of the American Academy of Ophthalmology, American Society of Retina Specialists, German Ophthalmological Society and Polish Ophthalmological Society. He is involved in anterior and posterior segment of the eye diagnosis and treatment, and works at Jasne Blonia Eye Clinic, in Lodz, Poland, and the K. Jonscher Hospital also in Lodz, Poland. Professor Nawrocki has written more than 100 scientific papers and created the Inverted ILM Flap Technique for Macular Hole Surgery. He also regularly presents at specialist meetings and conferences across the world.
Which instrument do you most value and which features make this instrument so effective?
The Eckardt ILM peeling forceps. I have tried many other forceps, but am most comfortable with the Eckardt.
Which instrument or procedure currently proves the most challenging to you in your daily practice? What could be improved?
Each procedure has its limitations and advantages. All can be challenging, depending on the individual case. I am happy with most instruments.
What experience have you had of working directly with companies to develop new instruments and/or surgical techniques? What are the benefits and/or limitations of working directly with companies?
I like working directly with companies and have discussed some aspects of developing instrumentation. I have not experienced any problems with this. I have noticed a difference between European companies and American ones in this respect though. I think European ones are more open for discussion. I also regularly give feedback to companies on new instruments.
What do you expect to see developing in the future (e.g. the next 3-5 years) in VR surgery?
I think it is already a very well developed field with a wide variety of instruments. I do not know what might come next.
What are your own priority focus areas for the next few years- either in research or clinical practice?
My priority is imaging VR interfaces. Imaging has already made tremendous improvements. Now OCT is already much better than in the past. I envisage this technique, however, to still be in its infancy. I anticipate that it will develop fast over the next few years for diagnostics and surgery. We will see a lot of new OCT applications without dyes. It could change our field.
Do you think that Vitreq instrumentation will be valuable in your own work in the future?
I hope so! Management of Vitreq understands a lot of problems and can hopefully continue to deliver developments that help to advance our specialist field. I strongly believe it is good company which will always try to achieve the best.
What do you envisage Vitreq’s role in the market to be?
Vitreq has good instruments and the potential to develop a good role in the market. I don’t see why it shouldn’t become a leading company. I wish Vitreq all the best in growing.